|
gptkbp:instanceOf
|
gptkb:brand
antidepressant
|
|
gptkbp:activeIngredient
|
mirtazapine
|
|
gptkbp:approvedBy
|
1996
|
|
gptkbp:ATCCode
|
N06AX11
|
|
gptkbp:chemicalClass
|
antidepressant
|
|
gptkbp:contraindication
|
gptkb:monoamine_oxidase_inhibitors
|
|
gptkbp:countryOfOperation
|
gptkb:Australia
gptkb:Canada
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:eliminationHalfLife
|
20–40 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:form
|
gptkb:tablet
orally disintegrating tablet
|
|
gptkbp:genericAvailable
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Remeron
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Organon
|
|
gptkbp:mechanismOfAction
|
noradrenergic and specific serotonergic antidepressant (NaSSA)
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
constipation
dizziness
weight gain
drowsiness
dry mouth
increased appetite
|
|
gptkbp:usedFor
|
gptkb:major_depressive_disorder
insomnia
anxiety disorders
|
|
gptkbp:bfsParent
|
gptkb:Organon_&_Co._(2021)
|
|
gptkbp:bfsLayer
|
6
|